Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
Teva
Fuji
US Department of Justice
Colorcon

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,310,094

« Back to Dashboard

Which drugs does patent 6,310,094 protect, and when does it expire?

Patent 6,310,094 protects ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, BREVIBLOC, BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, and BREVIBLOC IN PLASTIC CONTAINER, and is included in two NDAs.

Protection for BREVIBLOC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in twenty-four countries.

Summary for Patent: 6,310,094
Title: Ready-to-use esmolol solution
Abstract:A ready-to-use injectable, aqueous pharmaceutical composition for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino) propoxy] phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture in a container, is disclosed.
Inventor(s): Liu; Jie (Scotch Plains, NJ), Pejaver; Satish K. (Bridgewater, NJ), Owoo; George (North Plainfield, NJ)
Assignee: Baxter International Inc. (Deerfield, IL)
Application Number:09/759,547
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,310,094
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,310,094
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process;

Drugs Protected by US Patent 6,310,094

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hq Spclt Pharma ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER esmolol hydrochloride SOLUTION;INTRAVENOUS 205703-002 Apr 7, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Hq Spclt Pharma ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER esmolol hydrochloride SOLUTION;INTRAVENOUS 205703-001 Apr 7, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-006 Feb 25, 2003 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
McKesson
Federal Trade Commission
Healthtrust
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.